These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30285763)

  • 1. Engrailed-2 (EN2) - a novel biomarker in epithelial ovarian cancer.
    McGrath SE; Annels N; Madhuri TK; Tailor A; Butler-Manuel SA; Morgan R; Pandha H; Michael A
    BMC Cancer; 2018 Oct; 18(1):943. PubMed ID: 30285763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
    Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
    BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
    Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
    Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
    Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF
    BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression.
    Li Q; Shi Y; Sa R; Hao J; Hu J; Xiao M; Wang C; Yan L; Qiao B; Chen G
    BMC Cancer; 2020 Jun; 20(1):555. PubMed ID: 32539763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of cyclase-associated actin cytoskeleton regulatory protein 2 in epithelial ovarian cancer correlates with aggressive histologic types and worse outcomes.
    Adachi M; Masugi Y; Yamazaki K; Emoto K; Kobayashi Y; Tominaga E; Banno K; Aoki D; Sakamoto M
    Jpn J Clin Oncol; 2020 Jun; 50(6):643-652. PubMed ID: 32211793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
    Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
    J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients.
    He J; Liu Y; Zhang L; Zhang H
    Med Sci Monit; 2018 Dec; 24():8933-8940. PubMed ID: 30531684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engrailed-2 might play an anti-oncogenic role in clear-cell renal cell carcinoma.
    Lai CY; Xu Y; Yu GS; Wu X; Li YF; Pan B; Heng BL; Xue YJ; Su ZX
    J Mol Histol; 2016 Jun; 47(3):229-37. PubMed ID: 26948025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer.
    Zhang M; Liu T; Xia B; Yang C; Hou S; Xie W; Lou G
    Int J Gynecol Cancer; 2018 Feb; 28(2):323-331. PubMed ID: 29240605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MMP-16 as a New Biomarker for Predicting Prognosis and Chemosensitivity of Serous Ovarian Cancer: A Study Based on Bioinformatics Analysis.
    Wang W; Liu Y; Yang Y; Huang X; Hou Y
    Crit Rev Eukaryot Gene Expr; 2021; 31(4):1-8. PubMed ID: 34587431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.
    Gou R; Zhu L; Zheng M; Guo Q; Hu Y; Li X; Liu J; Lin B
    J Transl Med; 2019 Sep; 17(1):275. PubMed ID: 31474227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
    Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
    Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
    Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
    EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sprouty 2 protein, but not Sprouty 4, is an independent prognostic biomarker for human epithelial ovarian cancer.
    Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
    Int J Cancer; 2015 Aug; 137(3):560-70. PubMed ID: 25630587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of GPNMB predicts an unfavorable outcome of epithelial ovarian cancer.
    Ma RQ; Tang ZJ; Ye X; Cheng HY; Sun KK; Chang XH; Cui H
    Arch Gynecol Obstet; 2018 May; 297(5):1235-1244. PubMed ID: 29428978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage.
    Muller P; Coates PJ; Nenutil R; Trcka F; Hrstka R; Chovanec J; Brychtova V; Vojtesek B
    J Ovarian Res; 2019 Mar; 12(1):30. PubMed ID: 30917858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.
    Zhao S; Dorn J; Napieralski R; Walch A; Diersch S; Kotzsch M; Ahmed N; Hooper JD; Kiechle M; Schmitt M; Magdolen V
    Biol Chem; 2017 Jun; 398(7):765-773. PubMed ID: 27935848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and clinical significance of transcription factor 4 (TCF4) in epithelial ovarian cancer.
    Liu L; Zeng Z; Yi J; Zuo L; Lv J; Yuan J; Lin Z; Luo R; Feng X
    Cancer Biomark; 2019; 24(2):213-221. PubMed ID: 30614797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.